Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

THR-317

08.20.19

Oxurion Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 in Combination with Ranibizumab for DME

Source: Oxurion NV

05.08.19

Oxurion Issues Financial and Business Update

Source: Oxurion NV

04.04.19

Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DME

Source: Oxurion NV

09.20.18

Oxurion Enrolls First Patient in Phase 2 Study Evaluating THR-317 for Treatment of Idiopathic Macular Telangiectasia Type 1

Source: Oxurion

09.17.18

Oxurion to Present Scientific Findings Supporting Therapeutic Potential of THR-317 and THR-687 at EURETINA

Source: Oxurion NV

04.27.18

ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DME

Source: ThromboGenics

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.